Ranolazine - Moligand™, 10mM in DMSO , Sodium channel protein type IV alpha subunit blocker, CAS No.95635-55-5, Sodium channel protein type IV alpha subunit blocker

CAS: 95635-55-5 Cat. No.: R408200 Formule: C₂₄H₃₃N₃O₄ Poids moléculaire: 427.54 Numéro CE: 620-450-7 PubChem CID: 56959

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

CVT 303, RS 43285-003 | N-​(2,​6-​dimethylphenyl)​-​4-​[2-​hydroxy-​3-​(2-​methoxyphenoxy)​propyl]​-1-​piperazineacetamide

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Vue d’ensemble

Information

Ranolazine Ranolazine (CVT 303, RS 43285-003) is a calcium uptake inhibitor via the sodium/calcium channel , used to treat chronic angina.
In vitro

Ranolazine\xa0is found to bind more tightly to the inactivated state than the resting state of the\xa0sodium\xa0channel underlying I(NaL), with apparent dissociation constants K(dr)=7.47 mM and K(di)=1.71 mM, respectively.\xa0Ranolazine\xa0at 5 mM and 10 mM reversibly shortens the duration of TCs and abolishes the after\xa0contraction. Ranolazine inhibits the\xa0late\xa0component of\xa0INa\xa0and attenuates prolongation of action potential duration when\xa0late\xa0INa\xa0is increased, both in the absence and presence of IK-blocking drugs. Ranolazine\xa0(10 mM) reduces by 89% the 13.6-fold increase in variability of APD caused by 10 nM ATX-II.

In vivo

Ranolazine\xa0significantly and reversibly shortens the action potential duration (APD) of\xa0myocytes\xa0stimulated at either 0.5 or 0.25 Hz in a concentration-dependent manner in left ventricular myocytes of dogs. Ranolazine (10 mM)\xa0significantly increases glucose\xa0oxidation\xa01.5-fold to 3-fold under conditions in which the contribution of\xa0glucose\xa0to overall ATP production is low (low Ca, high FA, with insulin), high (high Ca, low Fa, with pacing), or intermediate in working heart of rats. Ranolazine\xa0(10 mM) similarly increases\xa0glucose\xa0oxidation in normoxic\xa0Langendorff\xa0hearts\xa0(high Ca, low FA; 15 mL/min) of rats. Ranolazine\xa0significantly improves functional outcome in\xa0reperfused\xa0ischemic\xa0working\xa0hearts, which is associated with significant increases in\xa0glucose\xa0oxidation.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Synonymes

CVT 303, RS 43285-003 | N-​(2,​6-​dimethylphenyl)​-​4-​[2-​hydroxy-​3-​(2-​methoxyphenoxy)​propyl]​-1-​piperazineacetamide

Spécifications et pureté

Moligand™, 10mM in DMSO

Mécanismes biochimiques et physiologiques

Ranolazine (CVT 303, RS 43285-003) is a calcium uptake inhibitor via the sodium/calcium channel, used to treat chronic angina.

Conditions de stockage de stockage

Store at -80°C

Expédié en

Dry ice packs + Cold packs

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Grade

Moligand™

Type d'action

BLOCKER

Mécanisme d'action

Sodium channel protein type IV alpha subunit blocker

Noms et identifiants

• Isomères SMILES: CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O
• PubChem CID: 56959
• Poids moléculaire: 427.54

Cibles associées (humaines)

SCN5A Tclin Sodium channel protein type 5 subunit alpha (3 Activities)

Discover Target: SCN5A

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)